Lisaftoclax

5 trials 4 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

4 Recruiting

0 Completed trials

1 Sponsors

15 Countries

Phase III

Phase I/II

Phase III: 4 Phase I/II: 1

Indications tested

Myelodysplastic syndrome 1

Sponsors using this IMP

Ascentage Pharma Group Inc. 5

All trials

5 total

A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3) Pending

2024-516436-10-00 Phase III 3 countries Ascentage Pharma Group Inc.
A Worldwide Study Testing the New Drug Lisaftoclax for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma… Recruiting

2024-514084-26-00 Phase III 3 countries Ascentage Pharma Group Inc.
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting

2024-515654-25-00 Phase I/II 2 countries Ascentage Pharma Group Inc.
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Phase III 13 countries Ascentage Pharma Group Inc.
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Phase III 11 countries Ascentage Pharma Group Inc.

Showing 1–5 of 5 trials

← All drugs A–Z